MedTrace Logo

PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine

NCT03881644 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2020-06-22

No results posted yet for this study

Summary

The aim is to investigate the incidence of headache, migraine attacks and flushing after pituitary adenylate cyclase-activating peptide-38 (PACAP38) with and without treatment with sumatriptan in patients with migraine

Conditions

  • Migraine Without Aura

Interventions

DRUG

Imigran

All patients will undergo this intervention on one of two study days

OTHER

Isotonic Saline

All patients will undergo this intervention on one of two study days

OTHER

Pituitary adenylate cyclase-activating peptide-38

All patients will undergo this intervention on both study days

Sponsors & Collaborators

  • Danish Headache Center

    lead OTHER

Principal Investigators

  • Messoud Ashina, MD,PhD,DMSc · Danish Headache Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-17
Primary Completion
2019-12-07
Completion
2019-12-07

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03881644 on ClinicalTrials.gov